Category: clinical study retractions

Despite retraction, antipsychotics still effective, safe for dementia, says author

alzheimers-research-and-therapyResearchers have retracted a systematic review that suggested that antipsychotic drugs are effective and safe for patients with symptoms of dementia — but claim their re-analysis of the updated data still comes to the same conclusions.

According to the retraction notice in Alzheimer’s Research and Therapy, some participants were incorrectly included twice in the meta-analysis. 

The corresponding authors recently lost another paper for an entirely different reason — earlier this year, we reported on a retraction in Annals of Neurology for Jin-Tai Yu and Lan Tan, affiliated with the Ocean University of China, Qingdao University, and Nanjing Medical University in China. The authors pulled that paper after appearing to pass off others’ data as their own.

Here’s the retraction notice for the review, issued earlier this year: Continue reading Despite retraction, antipsychotics still effective, safe for dementia, says author

Authors fix three Diabetes papers flagged for image issues

diabetesResearchers have corrected three studies published in the journal Diabetes after users flagged issues with the images on PubPeer.

All three papers share a number of authors, including the same last and corresponding author, Aimin Xu, from The University of Hong Kong.

Since the corrections appear relatively extensive, we asked the journal if retractions were ever on the table. According to Chris Kohler, associate publisher, scholarly journals at American Diabetes Association, which publishes Diabetes, an ethical panel reviewed the papers before allowing the authors to issue the errata, all of which were published online this month: Continue reading Authors fix three Diabetes papers flagged for image issues

Macchiarini paper in Nature journal earns expression of concern for data questions

nature-communications-228x300Nature Communications has issued an expression of concern for a 2014 paper by beleaguered surgeon Paolo Macchiarini, citing concerns over whether the paper accurately reports the experiments that were carried out.

According to the notice, Macchiarini, a former rising star in the field of transplant medicine, agrees with the expression of concern. Three of his 22 co-authors have objected.

“Experimental orthotopic transplantation of a tissue-engineered oesophagus in rats” describes transplanting an esophagus into rats that was seeded with their own stem cells, and notes that all animals survived the study period (14 days), and gained more weight than rats given a placebo operation. It’s a topic Macchiarini has made famous, as the first surgeon to perform a similar procedure with a human tracheal transplant. But he’s faced charges of misconduct in the last few years, resulting in his dismissal from Karolinska Institutet (KI).

Here’s the text of the notice, scheduled to go live at 10 a.m. UK time today: Continue reading Macchiarini paper in Nature journal earns expression of concern for data questions

Authors retract (and replace) cardiac rehab study in JAMA journal

jama-internal-medicine

Researchers have retracted and replaced a 2014 paper in JAMA Internal Medicine after realizing a number of errors had affected the findings.

The authors note the mistakes do not have a significant impact on the overall proportion of heart patients who participated in cardiac rehab. However, a number of findings were affected, such as the difference in participation in cardiac rehab defined by race, and how the overall participation has changed throughout the years.

Therefore, JAMA Internal Medicine has published a lengthy notice of retraction and replacement, which explains the errors made in the original paper, and updated the first paper with a new version of the study.

The retraction and replacement notice, issued this week, starts: Continue reading Authors retract (and replace) cardiac rehab study in JAMA journal

Cancer researcher earns 5th retraction after misconduct finding

oncoimmunologyA cancer researcher has logged her fifth retraction following an investigation that concluded she had committed scientific misconduct.

We’ve previously reported on four retractions of papers by Stephanie Watkins, a researcher at Loyola Medicine. The previously issued notices — in The Journal of Clinical Investigation and Cancer Research — note that an investigation committee appointed by the National Institutes of Health (NIH) found Watkins to be solely responsible for the misconduct, with none of the co-authors aware of it.

The editor of OncoImmunology previously informed us that the journal was investigating another one of Watkins’ papers; the journal has now pulled that paper, citing “fabrication and falsification of data” in the original studies referenced in the paper.

Here’s the retraction notice, published online earlier this year: Continue reading Cancer researcher earns 5th retraction after misconduct finding

Retraction notice for GMO paper updated to include fraud

fns2015012717103119Earlier this year, a nutrition journal retracted an article about the potential dangers of eating food containing genetically modified organisms (GMOs), noting the paper contained a duplicated image.

At the time, news outlets in Italy were reporting accusations that the last author, Federico Infascelli, an animal nutrition researcher at the University of Naples, had falsified some of his research.

Food and Nutrition Sciences has now updated its initial notice, saying the paper was pulled for data fabrication. In addition, Infascelli is no longer listed on its editorial board – he is included on an archived link to the editorial board from March 2016, but not on the current list of members.

Here is the updated version of the retraction notice for “Gamma-Glutamyl Transferase Activity in Kids Born from Goats Fed Genetically Modified Soybean:” Continue reading Retraction notice for GMO paper updated to include fraud

Cardiovascular researcher in Taiwan logs four retractions

clinical-scienceA researcher has earned four retractions following an investigation at his institutions in Taiwan.

The retraction notices, which appear in Clinical Science, mention investigations into the work of Kou-Gi Shyu at the Shin-Kong Wu Ho-Su Memorial Hospital and Taipei Medical University (TMU).

Shyu is listed as being affiliated with both institutions in the original papers, but a TMU official told us Shyu left his teaching role at TMU amidst the probe. Shyr-Yi Lin, professor of medicine and dean of research and development at TMU, noted: Continue reading Cardiovascular researcher in Taiwan logs four retractions

CrossFit can sue over error in paper it claims cost the brand millions

court-caseA California court ruled that fitness empire CrossFit can proceed to trial with its lawsuit against a competitor, alleging it published falsified data that hurt the company’s reputation, according to recently released court documents.

The case pits the popular for-profit CrossFit brand against the non-profit National Strength and Conditioning Association (NSCA), which published the 2013 study in question.

CrossFit claims it lost upwards of $8 million afer researchers concluded that 16 percent of CrossFit participants in a small study left the exercise program because of injury. However, in a 2015 erratum, the authors – led by Steven T. Devor, director of the Exercise Science Laboratory at The Ohio State University — noted that follow up showed only 2 participants out of the 11 drop-outs mentioned their health as a reason.

The study appeared in the Journal of Strength & Conditioning Research, published by CrossFit competitor NSCA, which also promotes fitness programs.  CrossFit claims the results in the paper cost it revenues from people paying for seminars at CrossFit, Inc. affiliate gyms.

“CrossFit is now eager to go to trial. More eager than ever,” a CrossFit spokesperson told Retraction Watch: Continue reading CrossFit can sue over error in paper it claims cost the brand millions

Second paper about major blood pressure drug trial in Japan to be retracted

hr_cimageA second paper about a major randomized trial in Japanese patients with heart disease is being retracted, after an investigation reportedly found multiple problems with the paper.

As predicted by Pharma Japan, Hypertension Research is retracting a 2011 paper, already the subject of two errata. Although a spokesperson said she couldn’t say why the paper was being retracted, as the notice was still in production, editor Toshihiko Ishimitsu told us: Continue reading Second paper about major blood pressure drug trial in Japan to be retracted

Child psychiatrist flagged for misconduct loses two more papers

Mani PavuluriA child psychiatrist has lost two papers after an institutional investigation concluded that she intentionally misrepresented children’s medication history in her research.

In November 2015, we reported on a retraction for Mani Pavuluri in the Journal of Psychiatry & Neuroscience following a probe at the University of Illinois at Chicago, her institution, which concluded that there was a “preponderance of evidence” that Pavuluri had committed misconduct. 

After an “unanticipated event” took place during a study, three studies by Pavuluri were halted and a letter was sent out to 350 research subjects, informing them of errors in the work. At the time, the Illinois spokesperson noted that Pavuluri — who, according to her LinkedIn page, is a Distinguished Fellow of the American Academy of Child and Adolescent Psychiatry — was also asked to retract two 2013 studies in the Journal of Affective Disorders. Those papers have now been retracted, noting that Pavuluri “intentionally and knowingly” misrepresented children’s medication history.

Here’s the retraction notice for “Deficits in emotion recognition in pediatric bipolar disorder: The mediating effects of irritability:” Continue reading Child psychiatrist flagged for misconduct loses two more papers